Unlocking Value in Canada’s LOE Wave explores the market forces, competitive dynamics, and strategic decisions shaping the next major wave of pharmaceutical patent expiries in Canada. With approximately 180 products approaching loss of exclusivity between 2026 and 2030, companies face both significant risks and new growth opportunities.

In this white paper, you'll learn:

• How Canada's upcoming LOE wave will reshape the market, including the therapeutic areas, products, and revenue most exposed to generic and biosimilar competition.
• What drives post-LOE success, from stakeholder behavior and generic entry patterns to strategies that help innovators protect value and generics identify high-potential opportunities.
• How leading companies are using data-driven approaches to forecast competitive impact, prioritize opportunities, and make more informed commercialization decisions.

Featuring practical frameworks, market analysis, and real-world case studies, this report provides actionable insights for pharmaceutical leaders preparing for Canada's most significant LOE period in decades.